Mink Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
Revenue | $0 | $0 | $0 |
Gross Profit | -38 | -43 | -48 |
EBITDA | -2,556 | -2,844 | -4,188 |
EBIT | -2,595 | -2,887 | -4,237 |
Net Income | -2,602 | -2,887 | -4,237 |
Net Change In Cash | 0 | 0 | 0 |
Free Cash Flow | -2,073 | -941 | -1,569 |
Cash | 13,360,340 | 14,281 | 1,681 |
Basic Shares | 4,270 | 4,443 | 3,981 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $2,704,743 |
Gross Profit | -181 | -215 | -204 | -121 |
EBITDA | -12,305 | -10,569 | -22,253 | -27,869 |
EBIT | -12,487 | -10,784 | -22,457 | -27,991 |
Net Income | -12,494 | -10,784 | -22,457 | -27,991 |
Net Change In Cash | 0 | 0 | 0 | 2,704,743 |
Cost of Revenue | -19,272 | |||
Free Cash Flow | -5,925,168 | -9,555 | -15,836 | -19,116 |
Cash | 13,360,340 | 4,577 | 3,367 | 19,635 |
Basic Shares | 4,270 | 3,863 | 3,435 | 3,367 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.57 |
2025-12-31 | -$0.56 |
2025-09-30 | -$0.65 |
2025-06-30 | -$1.06 |